BOJI CRO(300404.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
BOJI CRO
300404.SZ
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. It offers pre-clinical research, clinical research, and other consulting services. The company also provides clinical drug production, pilot test scale-up, process verification batch production, and drug registration and approval services.
589.86 B
300404.SZMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking11/26
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.19%C
    • Profit Margin4.53%C
    • Gross Margin28.45%C
  • Growth ScoreA
    • Revenue YoY33.15%A
    • Net Profit YoY166.36%A
    • Total Assets YoY12.04%B
    • Net Assets YoY8.63%B
  • Cash ScoreB
    • Cash Flow Margin155.73%B
    • OCF YoY33.15%A
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreB
    • Gearing Ratio34.06%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%

    Wallstreetcn·
    SZ
    301230
    -1.55%
    SZ
    301333
    -1.97%
    SZ
    000516
    -2.40%
    Wallstreetcn·
    SZ
    301230
    -1.55%
    SZ
    301333
    -1.97%
    SZ
    000516
    -2.40%

    BOJI CRO released its performance for the first three quarters, with a net profit attributable to the parent company of 21.9139 million yuan, a decrease of 49.36%

    Zhitong·
    SZ
    300404
    -0.74%
    Zhitong·
    SZ
    300404
    -0.74%

    BOJI CRO: Subsidiary Guangzhou Huasheng Pharmaceutical has obtained a drug registration certificate

    Zhitong·
    SZ
    300404
    -0.74%
    Zhitong·
    SZ
    300404
    -0.74%

    Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

    Zhitong·
    SH
    603207
    -1.17%
    SZ
    300404
    -0.74%
    Zhitong·
    SH
    603207
    -1.17%
    SZ
    300404
    -0.74%

    BOJI CRO obtained an invention patent for the "Method for Determining Gallic Acid in Berberine."

    Zhitong·
    SZ
    300404
    -0.74%
    Zhitong·
    SZ
    300404
    -0.74%
    © 2026 Longbridge｜Disclaimer